Ventrus Biosciences (VTUS) develops new treatments for gastrointestinal (NYSE:GI) disorders with a lead product candidate (Diltiazem Topical Cream or VEN 307) that is currently being evaluated in the second of two planned pivotal Phase III clinical trial.
CLINICAL TRIAL CATALYSTS:
VTUS expects to report results from the second of two pivotal Phase III clinical trials (ClinicalTrials.gov ID NCT01690221) for the relief of pain associated with anal fissures during Q4 2013 to support a planned 505(b)(2) NDA filing for a novel topical formulation of an approved calcium channel blocker drug (diltiazem). Last May, EU partner S.L.A. Pharma reported positive results in the first Phase III clinical trial for VEN-307.
ClinicalTrials.gov IDs NCT01816529, NCT01821274 and NCT01816191 are...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|